ArticleToxicology reports2025
Piperlongumine mediated apoptosis in cervical cancer cells beyond docking predictions.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is the 4th most prevalent cancer in women. Despite its global health impact, cervical cancer research has achieved limited success with various therapies (chemo, radio, chemo-radio, surgery, etc.). Recent decades have seen no improvement in survival rates due to cancer recurrence and long-term health concerns. These treatments show the need for a new herbal approach as alternative therapy for cancer. Piperlongumine is one of numerous perfected phytochemicals with anticancerous properties. In this study, in silico simulations demonstrate various novel properties of Piperlongumine. Molecular docking was performed between receptor and ligand by simulating molecular interactions in the pro and anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and Bcl-2 antagonist/killer (Bak). The docking scores of Piperlongumine with Bcl-2, Bak, and Bax are -7.02, -6.78, and -7.54 kcal/mol, respectively. Piperlongumine was also bio-tested for anticancer activities against cervical cancer cells (SiHa). Piperlongumine showed compromised cell viability, promoted apoptosis, higher nuclear condensation, reduction in mitochondrial membrane potential, increase in reactive oxygen species level, promoted cell cycle arrest, upregulation of pro-apoptotic gene whereas downregulation of anti-apoptotic genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.